These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

90 related items for PubMed ID: 724180

  • 1. Fibrin degradation products and the diagnosis of ovarian carcinoma.
    Anstey JT, Blythe JG.
    Obstet Gynecol; 1978 Nov; 52(5):605-8. PubMed ID: 724180
    [Abstract] [Full Text] [Related]

  • 2. Serum fibrinogen/fibrin degradation products in patients with ovarian carcinoma.
    Lalos O, Frankendal B, Rudolphi O.
    Ann Chir Gynaecol; 1977 Nov; 66(3):131-134. PubMed ID: 327909
    [Abstract] [Full Text] [Related]

  • 3. The preoperative diagnosis of malignancy of ovarian cysts.
    Tropé C.
    Neoplasma; 1981 Nov; 28(1):117-21. PubMed ID: 7279055
    [Abstract] [Full Text] [Related]

  • 4. [The clinical significance of thrombin-antithrombin III complex (TAT) and fibrinogen and fibrin degradation products (FDP) levels in ovarian cancer].
    Sawaguchi K, Hojo T, Nozaki S, Yabushita H, Noguchi M, Nakanishi M.
    Nihon Sanka Fujinka Gakkai Zasshi; 1992 Jan; 44(1):73-8. PubMed ID: 1541865
    [Abstract] [Full Text] [Related]

  • 5. Fibrinogen/fibrin degradation products in serum of patients with idiopathic thrombocytopenic purpura: elevated levels during severe thrombocytopenic phase of the disease.
    Nagasawa T, Kono I, Sakurai T, Kashiwagi H.
    Thromb Haemost; 1976 Jun 30; 35(3):628-34. PubMed ID: 989969
    [Abstract] [Full Text] [Related]

  • 6. Preoperative evaluation of D-dimer and CA 125 levels in differentiating benign from malignant ovarian masses.
    Gadducci A, Baicchi U, Marrai R, Ferdeghini M, Bianchi R, Facchini V.
    Gynecol Oncol; 1996 Feb 30; 60(2):197-202. PubMed ID: 8631538
    [Abstract] [Full Text] [Related]

  • 7. Unreliability of current serum fibrin degradation product (FDP) assays.
    Gaffney PJ, Perry MJ.
    Thromb Haemost; 1985 Jun 24; 53(3):301-2. PubMed ID: 3901388
    [Abstract] [Full Text] [Related]

  • 8. Early diagnosis of ovarian cancer.
    Popkin DR.
    Can Med Assoc J; 1979 May 05; 120(9):1106-8. PubMed ID: 445304
    [Abstract] [Full Text] [Related]

  • 9. [Markerfunction of crosslinked fibrin derivatives in ascitic fluid from patients with ovarian cancer: a comparison with ascitic fluid in liver cirrhosis].
    Graeff H, Klaubert W, Klaubert E, Gollwitzer R, von Hugo R, Hafter R.
    Geburtshilfe Frauenheilkd; 1983 Jun 05; 43 Suppl 1():42-6. PubMed ID: 6555132
    [Abstract] [Full Text] [Related]

  • 10. New enzyme immunoassay of fibrin-fibrinogen degradation products in plasma using a monoclonal antibody.
    Koopman J, Haverkate F, Koppert P, Nieuwenhuizen W, Brommer EJ, Van der Werf WG.
    J Lab Clin Med; 1987 Jan 05; 109(1):75-84. PubMed ID: 3540164
    [Abstract] [Full Text] [Related]

  • 11. ThinPrep evaluation of fluid samples aspirated from cystic ovarian masses.
    Lu D, Davila RM, Pinto KR, Lu DW.
    Diagn Cytopathol; 2004 May 05; 30(5):320-4. PubMed ID: 15108229
    [Abstract] [Full Text] [Related]

  • 12. Fibrinolysis in idiopathic menorrhagia.
    Bisht D, Gupta SC, Kaushik S, Ganguli G, Mital VP.
    Indian J Pathol Microbiol; 1991 Jul 05; 34(3):200-2. PubMed ID: 1818856
    [Abstract] [Full Text] [Related]

  • 13. [Critical evaluation of new methods for studying fibrin degradation products].
    Prisco D.
    Recenti Prog Med; 1989 May 05; 80(5):263-7. PubMed ID: 2669062
    [Abstract] [Full Text] [Related]

  • 14. Pretreatment plasma levels of fibrinopeptide-A (FPA), D-dimer (DD), and von Willebrand factor (vWF) in patients with ovarian carcinoma.
    Gadducci A, Baicchi U, Marrai R, Del Bravo B, Fosella PV, Facchini V.
    Gynecol Oncol; 1994 Jun 05; 53(3):352-6. PubMed ID: 8206409
    [Abstract] [Full Text] [Related]

  • 15. Clinical utility of serum fibrinogen degradation products (FDP) in the diagnostic and prognostic evaluation of oral cancer.
    Ghosh M, Aroor AR, Raghavan MR.
    Ann Dent; 1990 Jun 05; 49(2):11-2, 45. PubMed ID: 2278474
    [Abstract] [Full Text] [Related]

  • 16. [Differentiation of fibrinolysis and fibrinogenolysis by analysis of FDP fragments].
    Okumura N, Furuwatari C, Ishikawa S, Furihata K, Katsuyama T, Kanai M, Nakahata T, Saitoh H.
    Rinsho Byori; 1992 Jul 05; 40(7):789-94. PubMed ID: 1507499
    [Abstract] [Full Text] [Related]

  • 17. TPS and CA 125 levels in serum, cyst fluid and ascites of patients with epithelial ovarian neoplasms.
    Harłozinska A, Sedlaczek P, Van Dalen A, Rozdolski K, Einarsson R.
    Anticancer Res; 1997 Jul 05; 17(6D):4473-8. PubMed ID: 9494553
    [Abstract] [Full Text] [Related]

  • 18. Blood coagulation abnormalities associated with envenoming by Trimeresurus albolabris in Hong Kong.
    Chan JC, Kwok MM, Cockram CS, Prematilleke MN, Tomlinson B, Critchley JA.
    Singapore Med J; 1993 Apr 05; 34(2):145-7. PubMed ID: 8266156
    [Abstract] [Full Text] [Related]

  • 19. The measurement of plasma D-dimer (DD) levels in the follow-up of patients with ovarian cancer.
    Gadducci A, Marrai R, Baicchi U, Ferdeghini M, Fanucchi A, Facchini V, Genazzani AR.
    Anticancer Res; 1995 Apr 05; 15(6B):2683-6. PubMed ID: 8669847
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.